Q3 2025

Filed Nov 3, 2025 · 10-Q · 34 days after period end · 0001193125-25-262521

Q3 2025 · 10-Q

Revenue

$45.87M

+267.0% vs Q3 2024

Net Income

-$60.72M

N/M vs Q3 2024

EPS Diluted

-$0.70

N/M vs Q3 2024

Operating Income-$57,426,000N/M

Operating Cash Flow

Same quarter

Metric	Q3 2025	Q3 2024	Q3 2023	Q3 2022
Revenue	$45.87M	$12.50M	$0.00	—
Net Income	-$60.72M	-$84.13M	-$51.15M	-$35.40M
EPS Diluted	-$0.70	-$0.98	-$0.73	-$0.58

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR